Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central anxious procedure, conolidine modulates alternate molecular targets. A Science Innovations analyze discovered that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://jasonf112tce7.wikilinksnews.com/user